Effect of high amylose resistant starch (HAM‐RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial

Abstract

Administration of HAM-RS2 for eight weeks significantly reduced levels of inflammatory and oxidative markers in hemodialysis patients confirming the results observed in CKD animals. Long term trials are needed to explore the impact of HAM-RS2 supplementation on clinical outcomes in end stage renal disease population.

Amylose resistant starch (HAM‐RS2) supplementation increases the proportion of Faecalibacterium bacteria in end‐stage renal disease patients: Microbial analysis from a randomized placebo‐controlled trial

“…As shown in our previous study, HAM-RS2-treated patients exhibited a significant reduction in serum concentrations in blood urea nitrogen (BUN). 9 Similarly, in a recent study, Sirich et al found a reduction of urea levels in their ESRD patients supplemented with amylose for 6 weeks. 13 The reduction in urea level with amylose supplementation may, in part, be due to SCFAs' trapping of ammonia, which was derived from hydrolysis of urea by urease-possessing colonic bacteria.…”

“…As shown in our previous study, HAM‐RS2‐treated patients exhibited a significant reduction in serum concentrations in blood urea nitrogen (BUN) . Similarly, in a recent study, Sirich et al found a reduction of urea levels in their ESRD patients supplemented with amylose for 6 weeks .…”

“…Supplementation with the prebiotic high‐amylose maize resistant starch type 2 (HAM‐RS2) fiber in CKD patients has been shown to attenuate oxidative stress, repair uremia‐induced disruption of colonic epithelial tight junction, and in murine models increase the population of SCFA‐producing bacteria . A recent double‐blind, parallel, randomized, placebo‐controlled trial conducted by our group demonstrated that HAM‐RS2 supplementation significantly lowers plasma urea and potassium concentrations and reduces biomarkers of inflammation and oxidative stress in end‐stage renal disease (ESRD) . Using fecal samples collected from a subgroup of patients enrolled in this trial, we sought to determine the effect of HAM‐RS2 supplementation on specific SCFA‐producing genera, namely Bifidobacteria , Prevotella , Parabacteroides , Ruminococcus , and Faecalibacterium , which are known to be abnormal in CKD patients, and have been shown to be altered by HAM‐RS2 supplementation in CKD animals …”

Effects of resistant starch interventions on circulating inflammatory biomarkers: a systematic review and meta-analysis of randomized controlled trials

“…Two researchers (MR and MV) independently evaluated the articles in the second screening stage and 185 studies that were not relevant were eliminated. Finally 13 studies with 14 effect sizes met the inclusion criteria and were included in the final analysis [17,18,20,[26][27][28][29][30][31][32][33][34][35].…”

“…Studies on the effect of resistant starch on inflammatory markers are conflicting. Some studies showed a significant decrease in inflammatory markers after RS consumption compared to placebo [17,18], but the results of some other studies were inconsistent [19,20].…”